Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07021794 · ClinicalTrials.gov registry record · Phase 2
SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)
A Phase 2 study of Post-COVID / Long-COVID, sponsored by Nancy Klimas.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07021794 is a Phase 2 study of Post-COVID / Long-COVID that is actively recruiting participants, run by Nancy Klimas. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07021794, a Phase 2 study of Post-COVID / Long-COVID, is actively recruiting participants, sponsored by Nancy Klimas.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Sipavibart
Study Locations (1)
Florida
- Nova Southeastern University - Fort Lauderdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07021794
The ClinicalTrials.gov registry entry for NCT07021794 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nancy Klimas, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post-COVID / Long-COVID appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07021794 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07021794 about?
NCT07021794 is a clinical study titled "SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)". This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.
What is the current status of trial NCT07021794?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-06-16. Estimated completion is 2026-12-31.
What conditions does trial NCT07021794 study?
This clinical trial studies the following conditions: Post-COVID / Long-COVID.
What interventions are being tested in trial NCT07021794?
The interventions under investigation include: Placebo (DRUG), Sipavibart (BIOLOGICAL).
Who is sponsoring clinical trial NCT07021794?
This trial is sponsored by Nancy Klimas, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07021794 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.